BUSINESS BITES: Zimmer becomes Zimmer Biomet; Amendia grows spine portfolio; Mindray MBO gathers pace

Zimmer has finally completed its merger with Biomet, creating Zimmer Biomet, the world's second largest orthopedics company after Johnson & Johnson's DePuy Synthes. The closing comes 14 months after Zimmer and Biomet's private equity owners inked the cash-and-equity deal. At that time, the deal was valued at around $13.35bn. Zimmer’s stock price has since risen over the past year and the final figure for the deal is closer to $14bn. The announcement follows the news that it was offloading the US business of its unicompartmental high flex knee (ZUK) line to Smith & Nephew, for an undisclosed sum. The transaction was part of Zimmer’s efforts to appease US anti-trust authorities. Additionally, DJO Global said it had entered into an agreement to purchase the Biomet Cobalt bone cement, Optivac Cement Mixing Accessories and Discovery elbow system for the US market. Discovery will be DJO’s first elbow technology. That deal will close within the next 10 days, DJO said.

Zimmer has finally completed its merger with Biomet, creating Zimmer Biomet, the world's second largest orthopedics company after Johnson & Johnson's DePuy Synthes. The closing comes 14 months after Zimmer and Biomet's private equity owners inked the cash-and-equity deal. At that time, the deal was valued at around $13.35bn. Zimmer’s stock price has since risen over the past year and the final figure for the deal is closer to $14bn. The announcement follows the news that it was offloading the US business of its unicompartmental high flex knee (ZUK) line to Smith & Nephew, for an undisclosed sum. The transaction was part of Zimmer’s efforts to appease US anti-trust authorities. Additionally, DJO Global said it had entered into an agreement to purchase the Biomet Cobalt bone cement, Optivac Cement Mixing Accessories and Discovery elbow system for the US market. Discovery will be DJO’s first elbow technology. That deal will close within the next 10 days, DJO said.

Zimmer also had to shed some EU units, selling ZUK’s European business to Italian company Lima in April; the...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Archive

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Cardiac catheter reuse targeted by FDA; lab testing of used catheters planned.

    REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.

  • Heart valve sewing cuffs to be developed:

    St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.

  • Nissho sales flat at only 1% in 1997:

    Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.

More from Medtech Insight